drugset / Trial / NCT04336098
Study of SRF617 in Patients With Advanced Solid Tumors
Phase 1
Completed
85 enrolled
Coherus Oncology, Inc.
Merck Sharp & Dohme LLC · collabSurface Oncology · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Phase 1, first-in-human, monotherapy and combination dose escalation and expansion study of SRF617.
Timeline
- Start
- 2020-03-16
- Primary completion
- 2023-08-25
- Completion
- 2023-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PERENOSTOBART | Monoclonal antibody | — | — |
| Background | Gemcitabine | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.